title: Antithrombotic therapy and survival in patients with malignant disease.
abstract: A broad range of studies suggest a two-way relationship between cancer and venous thromboembolism (VTE). Patients with cancer have consistently been shown to be at elevated risk for VTE; this risk is partly driven by an intrinsic hypercoagulable state elicited by the tumour itself. Conversely, thromboembolic events in patients without obvious risk factors are often the first clinical manifestation of an undiagnosed malignancy. The relationship between VTE and cancer is further supported by a number of trials and meta-analyses which, when taken together, strongly suggest that antithrombotic therapy can extend survival in patients with cancer by a mechanism that extends beyond its effect in preventing VTE. Moreover, accumulating evidence from in vitro and in vivo studies has shown that tumour growth, invasion, and metastasis are governed, in part, by elements of the coagulation system. On 22 May 2009, a group of health-care providers based in the United Kingdom met in London, England, to examine recent advances in cancer-associated thrombosis and its implications for UK clinical practice. As part of the discussion, attendees evaluated evidence for and against an effect of antithrombotic therapy on survival in cancer. This paper includes a summary of the data presented at the meeting and explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a consensus statement developed by the group.
authors.affiliation: Thrombosis Research Institute and Queen Mary University of London, Emmanuel Kaye Building Manresa Road, London SW3 6LR, UK. akkakkar@tri-london.ac.uk
authors.forename: A K
authors.initials: AK
authors.lastname: Kakkar
authors.forename: F
authors.initials: F
authors.lastname: Macbeth
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000401:mortality*; D054556:Venous Thromboembolism / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight
references.citation: Cancer. 1994 Jul 1;74(1):38-45
references.pmid: 8004580
references.citation: Nat Clin Pract Oncol. 2005 Jul;2(7):356-63
references.pmid: 16075795
references.citation: Br J Surg. 1999 Jul;86(7):890-4
references.pmid: 10417560
references.citation: J Clin Invest. 1992 May;89(5):1469-77
references.pmid: 1373740
references.citation: J Thromb Haemost. 2007 Apr;5(4):729-37
references.pmid: 17408406
references.citation: Ann Intern Med. 1999 May 18;130(10):800-9
references.pmid: 10366369
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2130-5
references.pmid: 15699479
references.citation: Oncogene. 2004 Jan 15;23(2):410-7
references.pmid: 14724569
references.citation: Am J Med. 1996 Mar;100(3):269-77
references.pmid: 8629671
references.citation: J Clin Invest. 1994 Sep;94(3):1320-7
references.pmid: 7521887
references.citation: Lancet Oncol. 2007 May;8(5):395-402
references.pmid: 17466896
references.citation: J Clin Oncol. 2004 May 15;22(10):1944-8
references.pmid: 15143088
references.citation: Int J Cancer. 2004 Dec 20;112(6):994-1002
references.pmid: 15386437
references.citation: Cancer. 1984 May 15;53(10):2046-52
references.pmid: 6322957
references.citation: J Clin Oncol. 1989 Aug;7(8):993-1002
references.pmid: 2547030
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5339-45
references.pmid: 14614019
references.citation: Mayo Clin Proc. 2006 Jun;81(6):758-67
references.pmid: 16770976
references.citation: Am J Physiol. 1997 Jul;273(1 Pt 1):C239-45
references.pmid: 9252462
references.citation: J Thromb Haemost. 2004 Aug;2(8):1266-71
references.pmid: 15304029
references.citation: Nat Med. 1996 Feb;2(2):209-15
references.pmid: 8574967
references.citation: BMC Cancer. 2009 Oct 06;9:355
references.pmid: 19807917
references.citation: N Engl J Med. 2000 Jun 29;342(26):1953-8
references.pmid: 10874063
references.citation: Br J Surg. 1995 Aug;82(8):1101-4
references.pmid: 7648165
references.citation: J Cell Biol. 1998 Mar 9;140(5):1241-53
references.pmid: 9490735
references.citation: Lancet. 1992 Jun 13;339(8807):1476
references.pmid: 1351142
references.citation: J Clin Oncol. 1997 Nov;15(11):3378-87
references.pmid: 9363869